What is the expected size of the CAR T-cell therapy market in 2026?

The CAR T-cell therapy market is expected to be valued at around US$ 6.1 billion in 2026.

What are the major drivers of the CAR T-cell therapy market?

Rising global cancer burden and expanding regulatory approvals and label extensions for therapies such as Carvykti and Abecma are major factors driving market growth.

Which region leads the CAR T-cell therapy market?

North America is likely to lead the CAR T-cell therapy market, accounting for nearly 36% share in 2026, supported by strong regulatory frameworks and the presence of certified treatment centers.

What is a key opportunity within the CAR T-cell therapy market?

Growing adoption of allogeneic, off-the-shelf CAR T-cell technologies presents a significant opportunity, as reduced manufacturing complexity is expected to improve affordability and patient access.

Who are the key players operating in the CAR T-cell therapy market?

Key players include Gilead Sciences, Inc., Novartis AG, Bristol-Myers Squibb Company, Legend Biotech Corporation, and Cellectis S.A., among others.

Table of Content - CAR T-Cell Therapy Market Size, Share, and Growth Forecast 2026

Executive Summary
1. Global CAR T-Cell Therapy Market Snapshot 2026 and 2033
2. Market Opportunity Assessment, 2026-2033, US$ Bn
3. Key Market Trends
4. Industry Developments and Key Market Events
5. Demand Side and Supply Side Analysis
6. PMR Analysis and Recommendations
Market Overview
1. Market Scope and Definition
2. Value Chain Analysis
3. Macro-Economic Factors
  1. Global GDP Outlook
  2. Global Healthcare Expenditure
4. Forecast Factors – Relevance and Impact
5. Product Adoption Analysis
6. PESTLE Analysis
7. Porter's Five Forces Analysis
8. Disease Epidemiology
9. Regulatory and Technology Landscape
Market Dynamics
1. Drivers
2. Restraints
3. Opportunities
4. Trends
Global CAR T-Cell Therapy Market Outlook: Historical (2020 – 2025) and Forecast (2026 – 2033)
1. Key Highlights
2. Global CAR T-Cell Therapy Market Outlook: Drug Type
  1. Introduction/Key Findings
  2. Historical Market Size (US$ Bn) Analysis by Drug Type, 2020-2025
  3. Current Market Size (US$ Bn) Forecast, by Drug Type, 2026-2033
    1. Yescarta
    2. Kymriah
    3. Breyanzi
    4. Abecma
    5. Carvykti
    6. Tecartus
    7. Others
  4. Market Attractiveness Analysis: Drug Type
3. Global CAR T-Cell Therapy Market Outlook: Target Antigen
  1. Introduction/Key Findings
  2. Historical Market Size (US$ Bn) Analysis by Target Antigen, 2020-2025
  3. Current Market Size (US$ Bn) Forecast, by Target Antigen, 2026-2033
    1. CD19
    2. BCMA
    3. CD22
    4. CD33
    5. HER2
    6. HER1
    7. Others
  4. Market Attractiveness Analysis: Target Antigen
4. Global CAR T-Cell Therapy Market Outlook: Indication
  1. Introduction/Key Findings
  2. Historical Market Size (US$ Bn) Analysis by Indication, 2020-2025
  3. Current Market Size (US$ Bn) Forecast, by Indication, 2026-2033
    1. Lymphoma
    2. Leukemia
    3. Multiple Myeloma
    4. Acute Myeloid Leukemia (AML)
    5. Others
  4. Market Attractiveness Analysis: Indication
Global CAR T-Cell Therapy Market Outlook: Region
1. Key Highlights
2. Historical Market Size (US$ Bn) Analysis by Region, 2020-2025
3. Current Market Size (US$ Bn) Forecast, by Region, 2026-2033
  1. North America
  2. Europe
  3. East Asia
  4. South Asia & Oceania
  5. Latin America
  6. Middle East & Africa
4. Market Attractiveness Analysis: Region
North America CAR T-Cell Therapy Market Outlook: Historical (2020 – 2025) and Forecast (2026 – 2033)
1. Key Highlights
2. North America Market Size (US$ Bn) Forecast, by Country, 2026-2033
  1. U.S.
  2. Canada
3. North America Market Size (US$ Bn) Forecast, by Drug Type, 2026-2033
  1. Yescarta
  2. Kymriah
  3. Breyanzi
  4. Abecma
  5. Carvykti
  6. Tecartus
  7. Others
4. North America Market Size (US$ Bn) Forecast, by Target Antigen, 2026-2033
  1. CD19
  2. BCMA
  3. CD22
  4. CD33
  5. HER2
  6. HER1
  7. Others
5. North America Market Size (US$ Bn) Forecast, by Indication, 2026-2033
  1. Lymphoma
  2. Leukemia
  3. Multiple Myeloma
  4. Acute Myeloid Leukemia (AML)
  5. Others
Europe CAR T-Cell Therapy Market Outlook: Historical (2020 – 2025) and Forecast (2026 – 2033)
1. Key Highlights
2. Europe Market Size (US$ Bn) Forecast, by Country, 2026-2033
  1. Germany
  2. Italy
  3. France
  4. U.K.
  5. Spain
  6. Russia
  7. Rest of Europe
3. Europe Market Size (US$ Bn) Forecast, by Drug Type, 2026-2033
  1. Yescarta
  2. Kymriah
  3. Breyanzi
  4. Abecma
  5. Carvykti
  6. Tecartus
  7. Others
4. Europe Market Size (US$ Bn) Forecast, by Target Antigen, 2026-2033
  1. CD19
  2. BCMA
  3. CD22
  4. CD33
  5. HER2
  6. HER1
  7. Others
5. Europe Market Size (US$ Bn) Forecast, by Indication, 2026-2033
  1. Lymphoma
  2. Leukemia
  3. Multiple Myeloma
  4. Acute Myeloid Leukemia (AML)
  5. Others
East Asia CAR T-Cell Therapy Market Outlook: Historical (2020 – 2025) and Forecast (2026 – 2033)
1. Key Highlights
2. East Asia Market Size (US$ Bn) Forecast, by Country, 2026-2033
  1. China
  2. Japan
  3. South Korea
3. East Asia Market Size (US$ Bn) Forecast, by Drug Type, 2026-2033
  1. Yescarta
  2. Kymriah
  3. Breyanzi
  4. Abecma
  5. Carvykti
  6. Tecartus
  7. Others
4. East Asia Market Size (US$ Bn) Forecast, by Target Antigen, 2026-2033
  1. CD19
  2. BCMA
  3. CD22
  4. CD33
  5. HER2
  6. HER1
  7. Others
5. East Asia Market Size (US$ Bn) Forecast, by Indication, 2026-2033
  1. Lymphoma
  2. Leukemia
  3. Multiple Myeloma
  4. Acute Myeloid Leukemia (AML)
  5. Others
South Asia & Oceania CAR T-Cell Therapy Market Outlook: Historical (2020 – 2025) and Forecast (2026 – 2033)
1. Key Highlights
2. South Asia & Oceania Market Size (US$ Bn) Forecast, by Country, 2026-2033
  1. India
  2. Southeast Asia
  3. ANZ
  4. Rest of SAO
3. South Asia & Oceania Market Size (US$ Bn) Forecast, by Drug Type, 2026-2033
  1. Yescarta
  2. Kymriah
  3. Breyanzi
  4. Abecma
  5. Carvykti
  6. Tecartus
  7. Others
4. South Asia & Oceania Market Size (US$ Bn) Forecast, by Target Antigen, 2026-2033
  1. CD19
  2. BCMA
  3. CD22
  4. CD33
  5. HER2
  6. HER1
  7. Others
5. South Asia & Oceania Market Size (US$ Bn) Forecast, by Indication, 2026-2033
  1. Lymphoma
  2. Leukemia
  3. Multiple Myeloma
  4. Acute Myeloid Leukemia (AML)
  5. Others
Latin America CAR T-Cell Therapy Market Outlook: Historical (2020 – 2025) and Forecast (2026 – 2033)
1. Key Highlights
2. Latin America Market Size (US$ Bn) Forecast, by Country, 2026-2033
  1. Brazil
  2. Mexico
  3. Rest of LATAM
3. Latin America Market Size (US$ Bn) Forecast, by Drug Type, 2026-2033
  1. Yescarta
  2. Kymriah
  3. Breyanzi
  4. Abecma
  5. Carvykti
  6. Tecartus
  7. Others
4. Latin America Market Size (US$ Bn) Forecast, by Target Antigen, 2026-2033
  1. CD19
  2. BCMA
  3. CD22
  4. CD33
  5. HER2
  6. HER1
  7. Others
5. Latin America Market Size (US$ Bn) Forecast, by Indication, 2026-2033
  1. Lymphoma
  2. Leukemia
  3. Multiple Myeloma
  4. Acute Myeloid Leukemia (AML)
  5. Others
Middle East & Africa CAR T-Cell Therapy Market Outlook: Historical (2020 – 2025) and Forecast (2026 – 2033)
1. Key Highlights
2. Middle East & Africa Market Size (US$ Bn) Forecast, by Country, 2026-2033
  1. GCC Countries
  2. South Africa
  3. Northern Africa
  4. Rest of MEA
3. Middle East & Africa Market Size (US$ Bn) Forecast, by Drug Type, 2026-2033
  1. Yescarta
  2. Kymriah
  3. Breyanzi
  4. Abecma
  5. Carvykti
  6. Tecartus
  7. Others
4. Middle East & Africa Market Size (US$ Bn) Forecast, by Target Antigen, 2026-2033
  1. CD19
  2. BCMA
  3. CD22
  4. CD33
  5. HER2
  6. HER1
  7. Others
5. Middle East & Africa Market Size (US$ Bn) Forecast, by Indication, 2026-2033
  1. Lymphoma
  2. Leukemia
  3. Multiple Myeloma
  4. Acute Myeloid Leukemia (AML)
  5. Others
Competition Landscape
1. Market Share Analysis, 2025
2. Market Structure
  1. Competition Intensity Mapping
  2. Competition Dashboard
3. Company Profiles
  1. Gilead Sciences, Inc.
    1. Company Overview
    2. Product Portfolio/Offerings
    3. Key Financials
    4. SWOT Analysis
    5. Company Strategy and Key Developments
  2. Novartis AG
  3. Bristol-Myers Squibb Company
  4. Legend Biotech Corporation
  5. Cellectis S.A.
  6. Autolus Therapeutics Plc
  7. Adaptimmune Therapeutics plc
  8. Mustang Bio, Inc.
  9. Bellicum Pharmaceuticals, Inc.
  10. MaxCyte, Inc.
  11. Tessa Therapeutics
  12. Caribou Biosciences, Inc.
  13. Takeda Pharmaceutical Company Limited
  14. Sorrento Therapeutics, Inc.
  15. Poseida Therapeutics, Inc.
Appendix
1. Research Methodology
2. Research Assumptions
3. Acronyms and Abbreviations

CAR T-Cell Therapy Market Size, Share, and Growth Forecast 2026 - 2033

CAR T-Cell Therapy Market by Drug Type (Yescarta, Kymriah, Breyanzi, Abecma, Carvykti, Tecartus, Others), Target Antigen (CD19, BCMA, CD22, CD33, HER2, HER1, Others), Indication (Lymphoma, Leukemia, Multiple Myeloma, Acute Myeloid Leukemia (AML), Others), and Regional Analysis for 2026 - 2033

Quick Links

Our Partners

Secure Payments Through